Abb. 2: CLEAR-Studie: PASI-90-Ansprechen in Woche 52 unter Secukinumab verglichen mit Ustekinumab (modifiziert nach Blauvelt A et al., 74th AAD 2016, Washington, Late Breaking Poster)
Abb 2 KOM Novartis Cosentyx
This site is only for use by healthcare professionals. By continuing to view this site you are confirming that you are a healthcare professional.